Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avivit Cahn

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
Diabetes Care|January 11, 2022
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, et al.
Diabetes Care|March 3, 2021
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58Avivit Cahn, Itamar Raz, Lawrence A Leiter, et al.
Circulation|February 22, 2019
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes MellitusThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
Lancet (London, England)|November 15, 2018
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
American Heart Journal|June 15, 2018
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 TrialStephen D Wiviott, Itamar Raz, Marc P Bonaca, et al.
Diabetes, Obesity & Metabolism|January 12, 2018
DECLARE-TIMI 58: Participants' baseline characteristicsItamar Raz, Ofri Mosenzon, Marc P Bonaca, et al.
Diabetes Care|November 18, 2022
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58Rena Pollack, Itamar Raz, Stephen D Wiviott, et al.
JAMA Cardiology|April 14, 2021
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical TrialThomas A Zelniker, Itamar Raz, Ofri Mosenzon, et al.
European Heart Journal|August 24, 2021
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trialKazuma Oyama, Itamar Raz, Avivit Cahn, et al.
Diabetes Care|December 18, 2019
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 StudyAvivit Cahn, Ofri Mosenzon, Stephen D Wiviott, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
Diabetes Care|January 11, 2022
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, et al.
Diabetes Care|March 3, 2021
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58Avivit Cahn, Itamar Raz, Lawrence A Leiter, et al.
Circulation|February 22, 2019
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes MellitusThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
Lancet (London, England)|November 15, 2018
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
American Heart Journal|June 15, 2018
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 TrialStephen D Wiviott, Itamar Raz, Marc P Bonaca, et al.
Diabetes, Obesity & Metabolism|January 12, 2018
DECLARE-TIMI 58: Participants' baseline characteristicsItamar Raz, Ofri Mosenzon, Marc P Bonaca, et al.
Diabetes Care|November 18, 2022
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58Rena Pollack, Itamar Raz, Stephen D Wiviott, et al.
JAMA Cardiology|April 14, 2021
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical TrialThomas A Zelniker, Itamar Raz, Ofri Mosenzon, et al.
European Heart Journal|August 24, 2021
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trialKazuma Oyama, Itamar Raz, Avivit Cahn, et al.
Diabetes Care|December 18, 2019
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 StudyAvivit Cahn, Ofri Mosenzon, Stephen D Wiviott, et al.
Pageof 10